Michael Sension
Adherence to daily antiretroviral therapy (ART) can be challenging for some people with HIV (PWH). Therefore, finding an effective alternative to daily ART is a priority for researchers and clinicians who treat HIV. Three posters presented at CROI 2025, in San Francisco, indicate that the use of injectable long-acting cabotegravir plus rilpivirine (LA-CAB+RPV; Cabenuva, ViiV Healthcare), is an effective option because it is administered monthly or